N4 Pharma Plc, a specialist pharmaceutical company, engages in the reformulation of existing drugs and vaccines to enhance their performance. The company reformulates commercialized generic drugs; and delivers novel and existing vaccines. Its products pipeline includes Sildenafil, a clinical stage product for the treatment of erectile dysfunction; Sartans, a clinical stage product for the treatment of hypertension; and Aprepitant, a clinical stage anti-emetic drug for oncology and pain relief, as well as Nuvac and Nuvec vaccines. The company's product also pipeline consists of Paroxetine, a clinical stage anti-depressant drug for the treatment of hot flashes and night sweats in menopausal women; and Duoloxetine, a clinical stage anti-depressant drug for the treatment of premature ejaculation. N4 Pharma Plc is based in Chellaston, the United Kingdom.
Industry, Sector and Symbol
Industry Drug Manufacturers - Major
Sub-IndustryN/A
SectorMedical
SymbolLON:N4P
CUSIPN/A
Phone+44-1332-690061
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins1.05%
Return on Equity1.54%
Return on Assets1.46%
Miscellaneous
EmployeesN/A
Outstanding Shares74,710,000
Ultima (LON:N4P) Frequently Asked Questions
What is Ultima's stock symbol?
Ultima trades on the London Stock Exchange (LON) under the ticker symbol "N4P."
What price target have analysts set for N4P?
1 brokerages have issued 1-year price objectives for Ultima's stock. Their predictions range from GBX 12 to GBX 12. On average, they expect Ultima's share price to reach GBX 12 in the next year. View Analyst Ratings for Ultima.
Who are some of Ultima's key competitors?
Some companies that are related to Ultima include Biolase (BIOL), Vical (VICL), Cancer Genetics (CGIX), Microbot Medical (MBOT), ReWalk Robotics (RWLK), Actinium Pharmaceuticals (ATNM), Streamline Health Solutions (STRM), Cleveland BioLabs (CBLI), Surgical Innovations (SUN), OvaScience (OVAS), Kitov Pharma (KTOV), Jaguar Health (JAGX), Digirad (DRAD), Pernix Therapeutics (PTX), Innovus Pharmaceuticals (INNV), Neuralstem (CUR), Concordia International (CXRX) and Interpace Diagnostics Gr (IDXG).
Who are Ultima's key executives?
Ultima's management team includes the folowing people:
- Mr. Nigel James Theobald, Chief Exec. Officer and Director (Age 54)
- Mr. Paul Titley MRSC, C.Chem, Exec. Director
- Mr. Andrew Leishman, Head of Nuvec® Devel.
Has Ultima been receiving favorable news coverage?
News coverage about N4P stock has been trending somewhat positive this week, according to Accern Sentiment Analysis. The research firm ranks the sentiment of media coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Ultima earned a media sentiment score of 0.18 on Accern's scale. They also gave media coverage about the company an impact score of 46.79 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near future.
How do I buy shares of Ultima?
Shares of N4P and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is Ultima's stock price today?
One share of N4P stock can currently be purchased for approximately GBX 20.25.
How big of a company is Ultima?
Ultima has a market capitalization of £17.04 million.
How can I contact Ultima?
Ultima's mailing address is Weston House, 1 Bradgate Park View, DERBY, DE73 5UJ, United Kingdom. The company can be reached via phone at +44-1332-690061.
MarketBeat Community Rating for Ultima (N4P)
MarketBeat's community ratings are surveys of what our community members think about Ultima and other stocks. Vote "Outperform" if you believe N4P will outperform the S&P 500 over the long term. Vote "Underperform" if you believe N4P will underperform the S&P 500 over the long term. You may vote once every thirty days.
Ultima (LON:N4P) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
1 Wall Street analysts have issued ratings and price targets for Ultima in the last 12 months. Their average twelve-month price target is GBX 12The high price target for N4P is GBX 12 and the low price target for N4P is GBX 12. There are currently 1 hold rating for the stock, resulting in a consensus rating of "Hold."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Hold | Hold | Hold | Hold |
| Consensus Rating Score: | 2.00 | 2.00 | 2.00 | 2.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | GBX 12 | GBX 12 | GBX 12 | GBX 12 |
Ultima (LON:N4P) Consensus Price Target History
Ultima (LON:N4P) Analyst Ratings History
Show:
| Date | Brokerage | Action | Rating | Price Target | Details |
|---|
| 2/5/2018 | Beaufort Securities | Reiterated Rating | Speculative Buy | |  |
(Data available from 4/21/2016 forward)
Ultima (LON:N4P) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Ultima (LON N4P) Insider Trading and Institutional Ownership History
Ultima (LON N4P) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 11/10/2017 | Nigel Theobald | Insider | Buy | 56,656 | GBX 8 | £4,532.48 | | |
(Data available from 1/1/2013 forward)
Ultima (LON N4P) News Headlines
| Source: |
|
Ultima (LON:N4P) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Financials are not available for this stock.
Ultima (LON N4P) Stock Chart for Saturday, April, 21, 2018
Loading chart…
